Binding of Anisoylated Lys-Plasminogen Streptokinase Activator Complex to Cells in Culture

Summary

Anisoylated Lys-plasminogen streptokinase activator complex (APSAC) was purified from Eminase^® by chromatography on Superose-12. Purified APSAC did not significantly deacylate within 4 h at 4° C in solution as determined by hydrolysis of D-Val-L-leu-L-lys-p-nitroanilide HCl (S-2251). At 37° C, maximum amidase activity developed in 120 min; ε-amino-n-caproic acid (EACA) did not affect the apparent rate of APSAC deacylation but stabilized the streptokinase-plasmin(ogen) complex (SkPl) which formed. APSAC bound to C6 glioma cells and human umbilical vein endothelial cells (HUVECs) in culture. Binding was completely inhibited by EACA suggesting an essential role for the plasminogen kringle domains. Cell-associated APSAC deacylated to form active SkPl which hydrolyzed S-2251 and D-Val-Leu-Lys-7-amino-4-methyl coumarin. The rate of APSAC deacylation was increased when the APSAC was cell-associated. APSAC that was initially bound to C6 cells or HUVECs also activated ¹²⁵I-plasminogen. This activity may have reflected cell-associated APSAC or APSAC that dissociated into solution. Plasmin was recovered bound to cells and in solution. These studies demonstrate that APSAC associates with cell-surfaces and retains activity. In the circulation, cell-surfaces may provide a significant pharmacologic compartment for intravenously administered APSAC.

• References

• 1 Fears R. Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme complex. Semin Thromb Hemostas 1989; 15: 129-139
• 2 Hibbs MJ, Fears R, Ferres H, Standring R, Smith AG. Determination of the deacylation rate of p-anisoyl plasminogen streptokinase activator complex (APSAC, EMINASE) in human plasma, blood and plasma clots. Fibrinolysis 1989; 3: 235-240
• 3 Chibber BAK, Radek JT, Morris JP, Castellino FJ. Rapid formation of an anion-sensitive active site in stoichiometric complexes of streptokinase and human [Glu¹]plasminogen. Proc Natl Acad Sci USA 1986; 83: 1237-1241
• 4 Anonick PK, Vetter WH, Gonias SL. Kinetics of the reaction of streptokinase-plasmin complex with purified human and mouse α₂-macroglobulin. Biochem J 1989; 264: 745-752
• 5 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
• 6 Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemostas 1991; 66: 32-36
• 7 Ellis V, Scully M, Kakkar VV. Plasminogen activation initiated by single chain urokinase-type plasminogen activator. J Biol Chem 1989; 264: 2185-2188
• 8 Stephens RW, Pollanen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Ronne E, Behrendt N, Dano K, Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-1995
• 9 Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-11662
• 10 Gonias SL, Braud LL, Geary WA, VandenBerg SR. Plasminogen binding to rat hepatocytes in primary culture and to thin slices of rat liver. Blood 1989; 74: 729-736
• 11 Gonzalez-Gronow M, Stack S, Pizzo SV. Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. Arch Biochem Biophys 1991; 286: 625-628
• 12 Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by α₂-antiplasmin and α₂-macroglobulin. J Biol Chem 1991; 266: 12329-12336
• 13 Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem 1988; 263: 11928-11934
• 14 Humphries JE, Hall SW, VandenBerg SR, Gonias SL. Streptokinase-plasmin complex binds to plasminogen receptors on rat hepatocytes and human endothelium. Fibrinolysis 1991; 5: 171-176
• 15 Hall SW, VandenBerg SR, Gonias SL. Plasminogen carbohydrate side chains in receptor binding and activation: A study of C6 glioma cells and primary cultures of rat hepatocytes. J Cell Biochem 1990; 43: 213-227
• 16 Gonias SL, Einarsson M, Pizzo SV. Catabolic pathways for streptokinase, plasmin and streptokinase activator complex in mice.In vivo reaction of plasminogen activator with α₂-macroglobulin. J Clin Invest 1982; 70: 412-423
• 17 Castellino FJ, Sodetz JM, Brockway WJ, Siefring Jr. GE. Enzymes of clot lysis: Streptokinase. Methods Enzymol 1977; 45: 244-257
• 18 Humphries JE, Vasudevan J, Gonias SL. Fibrinogenolytic and fibrinolytic activity of cell-associated plasmin. Arterioscler Thromb 1993; 13: 48-55
• 19 Gonias SL, Figler NL, Braud LL. Regulation of streptokinase-human plasmin complex by the plasma proteinase inhibitors α₂-antiplasmin and α₂-macroglobulin is species specific and temperature dependent. Blood 1988; 72: 1658-1664
• 20 Standring R, Fears R, Ferres H. The protective effect of acylation on the stability of APSAC (Eminase) in human plasma. Fibrinolysis 1988; 2: 157-162
• 21 Fears R, Ferres H, Greenwood HC. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in the absence and presence of aspirin. Thromb Res 1990; 60: 259-268
• 22 Fears R, Ferres H, Standring R. Pharmacological comparison of anisoylated Lys-plasminogen streptokinase activator complex with its glu-plasminogen variant and streptokinase-glu-plasminogen: Binding to human fibrin and plasma clots. Fibrinolysis 1989; 3: 93-100